Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $177,097 - $249,770
7,578 New
7,578 $223,000
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $47,239 - $70,086
-1,819 Reduced 11.39%
14,154 $434,000
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $333,516 - $562,089
15,973 New
15,973 $470,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Corton Capital Inc. Portfolio

Follow Corton Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corton Capital Inc. with notifications on news.